Current examples of this strategy include Zolgensma® for spinal muscular atrophy and Luxturna® for RPE65-related retinal dystrophy, both of which are approved for listing, illustrating the safety and feasibility of this strategy for future applications. The gene discussed is RPE65; the disease is proximal spinal muscular atrophy.